29 June 2023 - The US FDA recently announced the launch of a year-long pilot programme regarding diagnostic methods within oncology ...
27 June 2023 - The Elecsys tTau/Abeta42 ratio helps clinicians define Alzheimer's disease biologically and expands Roche's Alzheimer's CSF portfolio to ...
23 June 2023 - Ultravist-300, -370 is now the only contrast agent in the US indicated to visualise known or suspected ...
30 May 2023 - Posluma will be commercially available in the United States in early June 2023. ...
22 May 2023 - The system visually highlights cancer that may have otherwise been left behind and is designed to be ...
16 March 2023 - Telix Pharmaceuticals today announces that the US FDA has approved a supplementary new drug application for ...
6 March 2023 - The Ventana PD-L1 (SP263) assay helps determine which patients with non-small cell lung cancer may be eligible ...
4 January 2023 - Foundation Medicine’s liquid biopsy test can now be used by oncologists to identify more patients with rare ...
4 January 2023 - OncoNano Medicine today announced that its lead clinical development candidate, pegsitacianine, a pH sensitive fluorescent nanoprobe ...
28 December 2022 - FDA approved indication includes both adolescents and adults representing a significant market opportunity ...
16 December 2022 - Cyralux is also the first and only targeted molecular imaging agent that illuminates ovarian cancer in ...
28 November 2022 - Definity is the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms. ...
14 November 2022 - Building on its contributions to newborn screening globally, PerkinElmer’s latest FDA authorised assay enables the simultaneous ...
24 October 2022 - Invivoscribe is pleased to announce that they have filed a supplemental pre-market approval submission with the ...
13 October 2022 - Telix Pharmaceuticals announces that Health Canada has approved Illuccix [kit for the preparation of gallium (Ga 68) ...